What is Nephros?
Founded in 1997 and headquartered in South Orange, New Jersey, Nephros specializes in the development and sale of high-performance liquid purification filters, known as ultrafilters. These devices are crucial for hospitals and medical clinics, providing an essential barrier against bacteria, viruses, and endotoxins in water systems for showers, sinks, and ice machines, thereby enhancing infection control protocols. Nephros's technology also serves dialysis centers, where its ultrafilters assist in removing biological contaminants from water and bicarbonate concentrate used in hemodialysis machines, ensuring patient safety and treatment efficacy.
How much funding has Nephros raised?
Nephros has raised a total of $20.3M across 6 funding rounds:
Stock Offering
$12.6M
Share Placement
$1.3M
Share Placement
$1.2M
Share Placement
$2.9M
Share Placement
$2M
Debt
$350K
Stock Issuance/Offering (2004): $12.6M, investors not publicly disclosed
Share Placement (2009): $1.3M led by Undisclosed
Share Placement (2015): $1.2M, investors not publicly disclosed
Share Placement (2018): $2.9M, investors not publicly disclosed
Share Placement (2019): $2M, investors not publicly disclosed
Debt (2020): $350K with participation from PPP
What's next for Nephros?
The recent strategic investment signals a pivotal moment for Nephros, likely enabling the company to accelerate its commercialization efforts, expand its product reach, and further innovate its ultrafilter technology. This capital infusion is expected to bolster its position in the healthcare sector, particularly in hospital-acquired infection prevention and dialysis water purification. Nephros's focus on critical medical applications suggests a trajectory aimed at scaling production, enhancing market penetration, and potentially exploring new therapeutic areas where advanced liquid purification is paramount.
See full Nephros company page
